Schizophrenia is arguably the most puzzling syndrome in medicine. Why do young adults develop chronic and bizarre signs and symptoms after decades of normal or near-normal development? The public health impact of schizophrenia is massive, with considerable mortality (life expectancy decreased by 12-15 years) 1 and enormous morbidity (in the top five leading causes of disease burden) 2, 3 in addition to the human pain that often follows in its wake. The fruits of a century of research into its etiology were few, and false leads were regrettably prominent, such as the urinary 'pink spot' 4 and early genetic linkage studies 5 . However, recent genetic studies 6, 7 have finally struck gold in the form of multiple associations that meet modern standards in human genetics for robustness and replication. New and upcoming data will probably extend the published findings and perhaps crack the genetics of schizophrenia wide open.
Recent genome-wide association studies highlight a provocative empirical findingschizophrenia is highly polygenic 8 . A parsimonious way to connect these many dots is through the hypothesis that distributed genetic variation in one (or perhaps several) pathways underlies risk for schizophrenia. At present, we can only be vague about the meaning of the term 'pathway'; current knowledge is limited, and the fundamental pathways could be biochemical, regulatory, developmental or anatomical and might correspond to a known pathway or a hitherto cryptic process. The idea arising from the observation of high polygenicity in schizophrenia is that the functional unit conferring risk may not be any single node but rather the pathway itself. Thus, schizophrenia may be a cardinal example of a pathway disease (Fig. 1) .
In schizophrenia research, as in much of genetics and molecular medicine, experimental methods usually focus on single loci or molecules. Such approaches are pragmatically reductionist and often highly informative in dissecting a more fundamental biological network link by link, edge by edge. However, what if liability to schizophrenia is conferred not by genetic variants in one or several loci but rather hundreds or even thousands of loci that together confer risk? What if the genetic risk for schizophrenia operates at the pathway level? Such a 'network medicine' paradigm 9 requires a rather different conceptualization of the nature of the disease.
What is the evidence that schizophrenia might be a pathway disease? First, the informal clinical surveillance network (hundreds of thousands of physicians taking family histories from millions of individuals with schizophrenia worldwide for a century) has not identified unequivocal Mendelian subforms of schizophrenia, in contrast to Mendelian forms identified for many common diseases such as Alzheimer's disease, breast cancer, autism and type 2 diabetes mellitus. Highly effortful genetic studies of rare, childhood-onset forms of schizophrenia have also not yet revealed Mendelian subforms-again in contrast to many other diseases where early onset has been a crucial clue. More than 20 years of ascertaining multiplex pedigrees for genetic studies has also failed to identify Mendelian subforms. Unpublished reports from relatively large sequencing studies of schizophrenia have not yet found compelling exonic mutations that might correspond to more tractable Mendelian subforms. It is impossible to prove the absence of Mendelian formsand some may eventually be found-but none has yet been identified.
Second, several genes implicated in schizophrenia and bipolar disorder, which now seems to be a genetic cousin of schizophrenia 8, 10 , are also associated with high-penetrance Mendelian variants, including TCF4, CACNA1C and possibly NRXN1. However, the clinical presentation of more Mendelian mutations in these genes does not include early-onset schizophrenia but rather mental retardation and/or autism 6, 11 . Thus, strong disruption to a node in a putative underlying pathway yields a different clinical presentation rather than a more severe and early-onset schizophrenia.
Third, the beginnings of a plausible network have emerged. There is now robust and replicable evidence for genetic variation near MIR137, the gene encoding the miRNA miR-137, in schizophrenia 6 . Intriguingly, four genes that had genome-wide significant associations in schizophrenia also contain binding sites for miR-137 (ref. 12). The genotypic relative risks were all 1.1-1.25, subtle effects typical for complex trait associations. Given the known roles of miR-137 in adult neurogenesis and neuronal
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Finally, schizophrenia is highly polygenic. We now know that polygenicity is a cardinal feature of many human diseases and anthropometric traits characterized by complex inheritance of dozens to hundreds of loci (for example, Crohn's disease, type 2 diabetes, height and body mass) 15 . The genetic variants involved are common with subtle effects, and some of these gene sets may have singular clinical utility. For schizophrenia, there is strong and replicated evidence that the number of loci is in the thousands 8 . Indeed, this polygenic component (that must include common variation rather than being a reflection of multiple rare variants) accounts for 23-33% of variance in liability to schizophrenia on the order of a third of the heritability 8, 16 . This also suggests that so-called 'missing heritability' is merely hidden and imperfectly assessed by current genotyping technologies.
A recent paper about nonsyndromic autism provided a tantalizing glimpse of how genetic variation might relate to altered biological pathways 17 . Typical patterns of gene expression in frontal and temporal cortex were attenuated in autism. An empirically derived gene expression module that was underexpressed in autism was enriched for known autism susceptibility genes and genetic association signals.
Although not completely elucidated, these data support the notion that polygenetic variation for autism alters the expression and regulation of a transcriptional network that mediates risk for autism. A similar model could hold for schizophrenia.
For schizophrenia, the hypothesis is that polygenetic variation alters a biological pathway. Removal of any single node through protein-killing mutation either may have no effect, owing to the emergent network property of robustness, or, for network hubs, may yield a phenotype other than schizophrenia, such as mental retardation or autism. There are many ways in which such a pathway could mediate liability to schizophrenia-by being insufficiently robust or overly rigid in response to environmental insult, for example, or by coding an inappropriate developmental program.
The conceptualization of schizophrenia as a pathway disease has an immediate implication.
A priority for the field 18 must be to complete genomic screens of a sufficient number of cases to define the pathway components with precision (for instance, 50,000 cases and 50,000 controls would afford power 19 similar to the GIANT height meta-analysis 20 ) . If this can be accomplished, it should be possible to develop assays to monitor pathway function in living cells. Knowledge derived from this work could lead to the fulfillment of the ultimate promise of genomics-primary prevention of the development of schizophrenia in those at risk and the development of more effective therapeutics in an era where big pharma has turned sharply away from psychiatric drug development.
Critically, it is possible that any such pathway is intrinsically modifiable and that people with schizophrenia are not 'doomed from the womb' but rather could anticipate return to relatively normal long-term function. More than a century after the initial description of schizophrenia as a clinical entity, the need for effective treatments is as pressing as ever. Though schizophrenia is widely recognized as a major cause of the global burden of disease 1 , affected individuals and clinicians continue to face an often chronic and debilitating condition with a mortality gap of more than 15 years.
